Literature DB >> 19535634

T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function.

Jonathan H Esensten1, Michael R Lee, Laurie H Glimcher, Jeffrey A Bluestone.   

Abstract

The transcription factor T-bet (Tbx21) is critical for Th1 polarization of CD4(+) T cells. Genetic deletion of Tbx21 can cause either exacerbation or attenuation of different autoimmune diseases in animal models. In the nonobese diabetic (NOD) mouse, genetic deletion of the Ifng or the Il12b (IL-12p40) genes, which are both critical Th1 cytokines, does not reduce the incidence of autoimmune diabetes. These results suggest that autoimmune diabetes in the NOD may not be a Th1-driven disease. However, we report that Tbx21 deficiency in the NOD mouse completely blocks insulitis and diabetes due to defects both in the initiation of the anti-islet immune response and in the function of CD4(+) effector T cells. We find defective priming of naive islet-reactive T cells by the innate immune system in Tbx21(-/-) animals. By contrast to naive cells, activated islet-reactive BDC2.5 TCR-transgenic T cells do not require Tbx21 in recipient animals for efficient adoptive transfer of diabetes. However, when these BDC2.5 TCR-transgenic effector cells lack Tbx21, they are less effective at entering the pancreas and promoting diabetes than Tbx21(+/+) cells. Tbx21(-/-) regulatory T cells function normally in vitro and diabetes can be restored in Tbx21(-/-) mice by reducing regulatory T cell numbers. Thus, the absence of diabetes in the NOD.Tbx21(-/-) is due to intrinsic defects in both T cells and cells of the innate immune system paired with the relative preservation of regulatory T cell function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535634      PMCID: PMC2732575          DOI: 10.4049/jimmunol.0804154

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system.

Authors:  Wendy S Garrett; Graham M Lord; Shivesh Punit; Geanncarlo Lugo-Villarino; Sarkis K Mazmanian; Susumu Ito; Jonathan N Glickman; Laurie H Glimcher
Journal:  Cell       Date:  2007-10-05       Impact factor: 41.582

2.  Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells.

Authors:  Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

3.  Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele.

Authors:  G Morahan; D Huang; S I Ymer; M R Cancilla; K Stephen; P Dabadghao; G Werther; B D Tait; L C Harrison; P G Colman
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

4.  Polygenic control of autoimmune diabetes in nonobese diabetic mice.

Authors:  S Ghosh; S M Palmer; N R Rodrigues; H J Cordell; C M Hearne; R J Cornall; J B Prins; P McShane; G M Lathrop; L B Peterson
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

5.  Antigen-driven effector CD8 T cell function regulated by T-bet.

Authors:  Brandon M Sullivan; Amy Juedes; Susanne J Szabo; Matthias von Herrath; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

6.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells.

Authors:  Hélène Bour-Jordan; Benoît L Salomon; Heather L Thompson; Gregory L Szot; Matthew R Bernhard; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

7.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

8.  T-bet is required for optimal proinflammatory CD4+ T-cell trafficking.

Authors:  Graham M Lord; Ravi M Rao; Hyeryun Choe; Brandon M Sullivan; Andrew H Lichtman; F William Luscinskas; Laurie H Glimcher
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

9.  Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis.

Authors:  Estelle Bettelli; Brandon Sullivan; Susanne J Szabo; Raymond A Sobel; Laurie H Glimcher; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2004-07-05       Impact factor: 14.307

10.  Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice.

Authors:  S Trembleau; G Penna; E Bosi; A Mortara; M K Gately; L Adorini
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  35 in total

Review 1.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

Review 2.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

3.  STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms.

Authors:  Alejandro V Villarino; Eugenio Gallo; Abul K Abbas
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

4.  Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice.

Authors:  Kristen E Pauken; Jonathan L Linehan; Justin A Spanier; Nathanael L Sahli; Lokesh A Kalekar; Bryce A Binstadt; James J Moon; Daniel L Mueller; Marc K Jenkins; Brian T Fife
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

Review 5.  T-bet in disease.

Authors:  Vanja Lazarevic; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2011-06-20       Impact factor: 25.606

6.  Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.

Authors:  Yanyan Qu; Lu Chen; Devin B Lowe; Walter J Storkus; Jennifer L Taylor
Journal:  Mol Ther       Date:  2012-01-03       Impact factor: 11.454

7.  Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells.

Authors:  Braxton L Jamison; Tobias Neef; Andrew Goodspeed; Brenda Bradley; Rocky L Baker; Stephen D Miller; Kathryn Haskins
Journal:  J Immunol       Date:  2019-05-20       Impact factor: 5.422

8.  B lymphocyte-induced maturation protein 1 (BLIMP-1) attenuates autoimmune diabetes in NOD mice by suppressing Th1 and Th17 cells.

Authors:  M-H Lin; F-C Chou; L-T Yeh; S-H Fu; H-Y C Chiou; K-I Lin; D-M Chang; H-K Sytwu
Journal:  Diabetologia       Date:  2012-10-07       Impact factor: 10.122

9.  Singular role for T-BET+CXCR3+ regulatory T cells in protection from autoimmune diabetes.

Authors:  Tze Guan Tan; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-21       Impact factor: 11.205

10.  Foxp3-independent mechanism by which TGF-β controls peripheral T cell tolerance.

Authors:  Soyoung A Oh; Ming Liu; Briana G Nixon; Davina Kang; Ahmed Toure; Michael Bivona; Ming O Li
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.